Subtopic Deep Dive
Hsp90 in Cancer Therapy
Research Guide
What is Hsp90 in Cancer Therapy?
Hsp90 in Cancer Therapy explores the role of Hsp90 chaperone in stabilizing oncogenic client proteins and the development of Hsp90 inhibitors as targeted chemotherapeutic agents.
Hsp90 inhibitors disrupt the folding and maturation of client proteins essential for cancer cell survival (Trepel et al., 2010, 1505 citations). Clinical trials of inhibitors like 17-AAG established maximum tolerated doses and dose-limiting toxicities in advanced solid tumors (Goetz et al., 2005, 334 citations). Over 10 key papers from 2002-2019 detail mechanisms, resistance, and combination therapies.
Why It Matters
Hsp90 inhibitors target multiple oncogenic pathways simultaneously by degrading client proteins like mutated kinases, offering advantages over single-target drugs in heterogeneous tumors (Trepel et al., 2010). Phase I trials of 17-AAG demonstrated antitumor activity in advanced cancers, informing ongoing combination strategies with radiotherapy (Goetz et al., 2005; Maier et al., 2016). Novel inhibitors disrupting Hsp90/Cdc37 complexes show promise against pancreatic cancer, addressing multi-target needs (Zhang et al., 2008). These advances support clinical translation in resistant tumors (Chatterjee and Burns, 2017).
Key Research Challenges
Acquired Drug Resistance
Cancer cells develop resistance to Hsp90 inhibitors through upregulated compensatory chaperones and altered client protein dependencies (Trepel et al., 2010). Combination therapies with MAPK inhibitors face mitochondrial biogenesis-mediated resistance (Zhang et al., 2016). Over 1500 citations highlight persistent clinical challenges.
Dose-Limiting Toxicities
Phase I trials identified hepatotoxicity and gastrointestinal effects as dose-limiting for 17-AAG, limiting efficacy (Goetz et al., 2005, 334 citations). Balancing therapeutic windows remains critical for solid tumors (Chatterjee and Burns, 2017).
Tumor Microenvironment Effects
Hsp90 inhibition alters tumor immunogenicity via HSP70 peptide cross-presentation to dendritic cells, but microenvironment hypoxia reduces efficacy (Noeßner et al., 2002; Yun et al., 2019). Integrating immunomodulatory roles requires further study (Zininga et al., 2018).
Essential Papers
Targeting the dynamic HSP90 complex in cancer
Jane B. Trepel, Mehdi Mollapour, Giuseppe Giaccone et al. · 2010 · Nature reviews. Cancer · 1.5K citations
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Suman Chatterjee, Timothy F. Burns · 2017 · International Journal of Molecular Sciences · 492 citations
Heat shock proteins (HSPs) are a large family of chaperones that are involved in protein folding and maturation of a variety of “client” proteins protecting them from degradation, oxidative stress,...
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization
Patrick Maier, Linda Hartmann, Frederik Wenz et al. · 2016 · International Journal of Molecular Sciences · 383 citations
During the last few decades, improvements in the planning and application of radiotherapy in combination with surgery and chemotherapy resulted in increased survival rates of tumor patients. Howeve...
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Tao Zhang, Adel Hamza, Xianhua Cao et al. · 2008 · Molecular Cancer Therapeutics · 367 citations
Abstract Pancreatic cancer is an aggressive disease with multiple biochemical and genetic alterations. Thus, a single agent to hit one molecular target may not be sufficient to treat this disease. ...
Heat Shock Proteins as Immunomodulants
Tawanda Zininga, Lebogang Ramatsui, Addmore Shonhai · 2018 · Molecules · 365 citations
Heat shock proteins (Hsps) are conserved molecules whose main role is to facilitate folding of other proteins. Most Hsps are generally stress-inducible as they play a particularly important cytopro...
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Matthew P. Goetz, David O. Toft, Joel M. Reid et al. · 2005 · Journal of Clinical Oncology · 334 citations
Purpose We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle ...
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Gao Zhang, Dennie T. Frederick, Lawrence W. Wu et al. · 2016 · Journal of Clinical Investigation · 298 citations
Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically ...
Reading Guide
Foundational Papers
Start with Trepel et al. (2010, 1505 citations) for Hsp90 complex overview, then Goetz et al. (2005, 334 citations) for clinical translation, and Zhang et al. (2008, 367 citations) for specific inhibitor mechanisms.
Recent Advances
Chatterjee and Burns (2017, 492 citations) on therapeutic approaches; Yun et al. (2019, 277 citations) on HSPs in cancer development.
Core Methods
Hsp90 inhibition via 17-AAG infusion (Goetz et al., 2005); Cdc37 complex disruption (Zhang et al., 2008); client protein degradation assays (Trepel et al., 2010).
How PapersFlow Helps You Research Hsp90 in Cancer Therapy
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map 1505-citation foundational work by Trepel et al. (2010) to recent inhibitors, revealing clusters around 17-AAG trials (Goetz et al., 2005) and pancreatic cancer applications (Zhang et al., 2008). exaSearch uncovers resistance mechanisms in underrepresented combination therapies; findSimilarPapers extends to 492-citation reviews like Chatterjee and Burns (2017).
Analyze & Verify
Analysis Agent employs readPaperContent on Goetz et al. (2005) to extract MTD/DLT data from 17-AAG trials, verified via verifyResponse (CoVe) against clinical endpoints. runPythonAnalysis processes citation networks or survival curves with pandas for statistical verification of inhibitor efficacy trends. GRADE grading scores evidence from phase I trials as moderate-quality due to small cohorts.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-Trepel et al. (2010), flagging contradictions between HSP70 immunomodulation (Zininga et al., 2018) and direct inhibition. Writing Agent uses latexEditText, latexSyncCitations for Goetz et al. (2005), and latexCompile to generate therapy review manuscripts; exportMermaid visualizes Hsp90 client degradation pathways.
Use Cases
"Analyze survival data from 17-AAG phase I trials and plot dose-response curves."
Research Agent → searchPapers('17-AAG phase I') → Analysis Agent → readPaperContent(Goetz 2005) → runPythonAnalysis(pandas/matplotlib on extracted endpoints) → matplotlib plot of MTD/DLT trends.
"Draft LaTeX review on Hsp90 inhibitors for pancreatic cancer with citations."
Research Agent → citationGraph(Trepel 2010, Zhang 2008) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structure) → latexSyncCitations(10 papers) → latexCompile(PDF review).
"Find GitHub repos implementing Hsp90 inhibitor simulations from papers."
Research Agent → searchPapers('Hsp90 inhibitor modeling') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (molecular dynamics code for Cdc37 disruption).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ Hsp90 papers, chaining searchPapers → citationGraph → GRADE grading to produce structured reports on inhibitor evolution from Goetz et al. (2005) to recent combinations. DeepScan's 7-step analysis verifies resistance claims in Zhang et al. (2016) with CoVe checkpoints and runPythonAnalysis on pathway data. Theorizer generates hypotheses on Hsp90/Cdc37 targeting in pancreatic tumors from Zhang et al. (2008).
Frequently Asked Questions
What defines Hsp90's role in cancer therapy?
Hsp90 stabilizes oncogenic clients like kinases; inhibitors induce their degradation (Trepel et al., 2010).
What are key Hsp90 inhibitors and methods?
17-AAG tested in phase I trials (Goetz et al., 2005); novel Cdc37 disruptors for pancreatic cancer (Zhang et al., 2008).
What are foundational papers?
Trepel et al. (2010, 1505 citations) on dynamic complex; Goetz et al. (2005, 334 citations) on clinical dosing.
What open problems exist?
Overcoming resistance via combinations and reducing toxicities (Chatterjee and Burns, 2017; Zhang et al., 2016).
Research Heat shock proteins research with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hsp90 in Cancer Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the Heat shock proteins research Research Guide